Mucus Clearance Devices Market By Product Type (High-Frequency Chest Wall Oscillation Systems, Positive Expiratory Pressure Devices, Oscillatory Positive Expiratory Pressure Devices, Mechanical Insufflation-Exsufflation Devices, Mechanical Percussion and Lung-Expansion Systems); By Application (Bronchiectasis, Cystic Fibrosis, Neuromuscular Disorders, Chronic Obstructive Pulmonary Disease, Primary Ciliary Dyskinesia, Acute and Postoperative Secretion Clearance); By End User (Homecare Settings, Hospitals, Outpatient Respiratory and Physiotherapy Centers, Long-Term Care and Post-Acute Facilities); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

Mucus Clearance Devices Market: Home-Based Airway Therapy Expands Beyond Traditional Cystic Fibrosis Care

The Global Mucus Clearance Devices Market was valued at USD 725.2 million in 2025 and is projected to reach USD 1.16 billion by 2032, growing at a CAGR of 6.9%, according to Strategic Market Research. This represents an absolute revenue increase of approximately USD 434.8 million and nearly 60% expansion over the forecast period.

 

The market covers products that mobilize or remove retained respiratory secretions, including high-frequency chest wall oscillation systems, positive expiratory pressure and oscillatory PEP devices, mechanical insufflation-exsufflation systems, and mechanical percussion or lung-expansion platforms. Based on Strategic Market Research estimates, HFCWO systems accounted for the largest product share of approximately 47.0% in 2025, equivalent to nearly USD 340.8 million, and are projected to expand at a CAGR of about 7.2% through 2032.

 

These devices are used primarily in cystic fibrosis, bronchiectasis, neuromuscular disorders, primary ciliary dyskinesia, and selected COPD patients with secretion retention or coexisting bronchiectasis. Hospitals also use certain systems for postoperative mucus plugging, atelectasis, ventilator dependence, and ineffective cough.

 

Purchasing patterns vary by product and care setting. Powered systems are supplied as durable medical equipment through purchase or rental reimbursement, while lower-cost handheld devices may generate more frequent replacement demand. PEP and oscillatory PEP products represented an estimated 24.0% of 2025 revenue, or approximately USD 174.0 million, and are projected to grow at a CAGR of around 6.5%. Garments, circuits, interfaces, hoses, filters, and other accessories add recurring revenue.

 

The market spans homecare placements, hospital procurement, rentals, replacements, accessories, and respiratory-support services. Homecare settings held an estimated 62.0% market share in 2025, representing approximately USD 449.6 million, and are forecast to grow at a CAGR of about 7.7%. Because complete annual shipment volumes are not publicly disclosed, utilization, payer claims, company revenue, and therapy adoption are more reliable indicators than unsupported unit estimates.

 

Cystic Fibrosis Remains the Most Clearly Defined Device Population

Cystic fibrosis provides the most established clinical pathway for routine airway clearance. The Cystic Fibrosis Foundation estimates that close to 40,000 children and adults live with the disease in the United States, while approximately 105,000 people have been diagnosed across 94 countries. Foundation guidance recommends airway clearance for all people with cystic fibrosis, although the preferred method is individualized because no single technique has demonstrated superiority for every patient.

Cystic fibrosis accounted for an estimated 25.0% of global mucus clearance device revenue in 2025, equivalent to approximately USD 181.3 million. The segment is projected to grow at a CAGR of around 5.3% through 2032, slower than bronchiectasis and neuromuscular applications because the diagnosed population is smaller and some patients receiving highly effective CFTR modulators are being assessed for treatment simplification.

The 2024 Cystic Fibrosis Foundation Patient Registry included 33,989 people. High-frequency chest wall oscillation was the primary airway-clearance method for 44.5% of registry participants, while PEP or oscillatory PEP accounted for 19.0%. Together, these device-based methods represented 63.5% of primary airway-clearance use. Applied to the registry population, the shares equal approximately 15,125 primary HFCWO users, 6,458 primary PEP or OPEP users, and 21,583 primary device-based users.

These figures measure registry therapy share rather than revenue or annual sales and exclude secondary methods, replacements, adherence, and patients outside the registry. They nevertheless show why cystic fibrosis remains the clearest indication for device adoption.

Improved survival is enlarging the adult cystic fibrosis population and extending the period of airway management. Adults represented 61.6% of the 2024 registry population, up from 60.4% in 2023. Treatment-simplification studies may reduce therapy burden for selected patients, but current guidance continues to support regular airway clearance and demand for shorter, portable systems. 

 

Bronchiectasis Becomes the Main Expansion Pathway

Non-cystic fibrosis bronchiectasis is becoming the largest application segment for mucus clearance devices. Strategic Market Research estimates that bronchiectasis accounted for approximately 38.0% of global market revenue in 2025, equivalent to nearly USD 275.6 million. The segment is projected to expand at a CAGR of about 8.0% through 2032, making it the fastest-growing application category.

A U.S. claims analysis estimated that between 340,000 and 522,000 adults were receiving treatment for bronchiectasis in 2013. Diagnosis creates a direct pathway to respiratory-therapy assessment, durable medical equipment qualification, and long-term airway-clearance management.

Utilization remains uneven. An EMBARC analysis covering 16,723 adults across 28 countries found that 8,739 patients, or 52.2%, received regular airway-clearance management. Only 2,748 participants used an airway-clearance device, equal to 16.4% of the full registry sample and approximately 31.4% of patients receiving regular airway-clearance management. The gap between clinical management and device use leaves room for better patient selection, stronger outcome evidence, and wider access through respiratory specialists and physiotherapy services.

The FDA approved brensocatib for non-cystic fibrosis bronchiectasis in August 2025, followed by European Commission authorization in November. The drug addresses inflammatory disease activity, while devices support secretion removal, making the pathways complementary for patients with continued mucus production. 

Bronchiectasis is also central to manufacturer growth strategies. Electromed identified adult pulmonology and bronchiectasis as its largest and fastest-growing target areas for fiscal 2026. This reflects a larger addressable population than cystic fibrosis, but adoption remains more dependent on imaging confirmation, symptom severity, prior treatment failure, payer documentation, and clinician preference. 

 

COPD Represents Scale, but Not Universal Device Eligibility

COPD creates the largest underlying respiratory population connected with the market. Approximately 14.2 million U.S. adults had physician-diagnosed COPD in 2021, while the global population has been estimated at approximately 392 million. Total prevalence, however, substantially overstates the addressable device market.

COPD and other chronic respiratory conditions represented an estimated 12.0% of market revenue in 2025, or approximately USD 87.0 million, and are forecast to expand at a CAGR of around 6.5% through 2032. The revenue share remains well below the disease’s population share because only a defined subgroup requires dedicated mucus-clearance equipment.

Dedicated mucus clearance is most relevant to patients with persistent sputum, recurrent infections, ineffective coughing, mucus plugging, or coexisting bronchiectasis. Medicare’s HFCWO policy makes this distinction explicit: COPD or chronic bronchitis without confirmed bronchiectasis does not satisfy the disease criterion for reimbursement. 

Commercial development in COPD depends on defined subgroups rather than the entire disease population. Imaging, recognition of COPD-bronchiectasis overlap, and specialist referral may expand eligibility, but no defensible device-use share is publicly available.

 

Neuromuscular Disease Supports a Specialized Cough-Assist Segment

Neuromuscular disorders accounted for an estimated 17.0% of global market revenue in 2025, representing approximately USD 123.3 million. The application segment is projected to grow at a CAGR of about 7.4%, supported by wider use of home ventilation, earlier respiratory assessment, and increasing recognition of cough-assist therapy in progressive neuromuscular conditions.

The U.S. National ALS Registry estimated close to 33,000 people with ALS in 2022, while global motor-neuron-disease prevalence has been modeled at approximately 273,000 people. Only the subgroup that develops clinically significant cough impairment becomes eligible for mechanical cough assistance, so prevalence cannot be converted directly into device share or revenue.

Mechanical insufflation-exsufflation systems represented an estimated 17.0% of product revenue in 2025, equal to approximately USD 123.3 million, and are expected to record the fastest product CAGR of around 7.5% through 2032. This smaller but expanding category supports powered equipment and recurring interfaces or circuits, with demand shaped by neurology, respiratory, home-ventilation, and rehabilitation programs.

 

HFCWO Systems Lead the High-Value Homecare Category

High-frequency chest wall oscillation systems represent the highest-value product category, with an estimated 47.0% share of the market in 2025 and revenue of approximately USD 340.8 million. The segment is forecast to grow at a CAGR of about 7.2% through 2032, supported by durable equipment pricing, reimbursement, garments, accessories, and long-term patient support.

Their use is established in cystic fibrosis and bronchiectasis, with additional demand from selected neuromuscular conditions. Higher revenue per placement also gives HFCWO systems a larger commercial position than their share of total users would suggest.

 

Handheld PEP and OPEP Devices Support Wider Accessibility

Positive expiratory pressure and oscillatory PEP devices accounted for an estimated 24.0% market share in 2025, equivalent to approximately USD 174.0 million. The segment is projected to expand at a CAGR of about 6.5% through 2032.

These devices occupy a lower-priced and more portable part of the market. Their smaller size and simpler distribution suit homecare, travel, outpatient therapy, and use alongside inhaled medication. Established products include Monaghan Medical’s AEROBIKA OPEP device and PARI’s PEP and O-PEP systems.

Revenue per placement is lower than for HFCWO, but replacement may occur more frequently. Performance depends on therapist recommendations, distribution, adherence, and inclusion in care protocols.

 

Integrated Airway-Clearance Platforms Extend into Acute Care

Mechanical percussion and lung-expansion platforms represented an estimated 12.0% of global revenue in 2025, equal to approximately USD 87.0 million, and are projected to grow at a CAGR of about 5.7% through 2032. Hospitals remain the main purchasing channel for these systems.

Hospitals require products for ventilated, tracheostomized, postoperative, or severely weakened patients who cannot use conventional home-based techniques. Acute, postoperative, and other applications accounted for an estimated 8.0% of market revenue in 2025, or approximately USD 58.0 million, and are expected to grow at a CAGR of around 5.8%.

The hospital-to-home model can extend revenue beyond the original placement through post-acute therapy, accessories, and support. Suppliers able to maintain continuity across settings may gain an advantage.

 

Homecare Generates the Strongest Revenue Visibility

Homecare settings held the largest estimated end-user share of 62.0% in 2025, representing approximately USD 449.6 million, and are forecast to expand at a CAGR of about 7.7% through 2032. Daily airway clearance is well suited to home use because chronic patients require repeated therapy rather than occasional hospital procedures. The setting also aligns with payer efforts to manage respiratory disease outside higher-cost acute care.

Hospitals represented an estimated 24.0% market share, or approximately USD 174.0 million, and are projected to grow at a CAGR of around 5.3%. Outpatient respiratory and physiotherapy centers accounted for approximately 9.0%, equivalent to USD 65.3 million, with an estimated CAGR of 6.0%. Long-term care and post-acute facilities represented the remaining 5.0%, or about USD 36.3 million, and are forecast to grow at approximately 6.5%.

Electromed reported fiscal 2025 revenue of USD 64.0 million, up 17.0% from USD 54.7 million in fiscal 2024. Direct homecare contributed USD 57.3 million, equal to approximately 89.5% of company revenue, and increased 15.7%. Hospital revenue reached USD 3.14 million, or 4.9% of revenue, after growing 23.9%. Homecare distributor revenue rose 58.1% to USD 2.93 million and represented about 4.6% of the total. The distributor channel grew fastest, but direct homecare remained the company’s main revenue base. 

Tactile Medical reported AffloVest revenue of USD 51.1 million in 2025, up from USD 33.6 million in 2024. This represents year-on-year growth of approximately 52.1%. AffloVest’s share of Tactile Medical revenue increased from 11% to 16%, a gain of five percentage points, while its lymphedema portfolio accounted for the remaining 84%.

 

Product Development and Competitive Landscape

Development is shifting toward portability, shorter sessions, comfort, and therapy documentation because these factors influence adherence and clinician confidence.

Baxter launched the Vest Advanced Pulmonary Experience system in the United States in 2024 as the next generation of its Hillrom platform. Electromed’s SmartVest Clearway received FDA 510(k) clearance in November 2022 and is sold across homecare and hospital channels. Tactile Medical competes through the battery-powered AffloVest, while Philips RespirTech offers the InCourage system. Monaghan Medical and PARI maintain established positions in handheld OPEP and PEP products, and ABM Respiratory Care is developing combined oscillation, lung-expansion, and aerosol-delivery systems.

The field includes diversified groups, respiratory specialists, and emerging developers. Electromed generated 99.6% of fiscal 2025 revenue in the United States, indicating domestic concentration, while Tactile Medical distributes AffloVest through respiratory DME providers. 

 

Regional Competition and Market Outlook Through 2032

North America held the largest estimated regional share of 44.0% in 2025, representing approximately USD 319.1 million, and is projected to expand at a CAGR of around 6.4% through 2032. The United States has the clearest commercial pathway through respiratory registries, device-specific reimbursement codes, home medical equipment suppliers, specialist referral networks, and public company disclosures.

Medicare, commercial insurers, Medicaid programs, Veterans Affairs, and private-pay channels support access, but documentation and payer operations add cost. Growth is likely to be concentrated in diagnosed bronchiectasis, COPD-bronchiectasis overlap, adult cystic fibrosis care, and home management of neuromuscular weakness.

Europe represented an estimated 27.0% of global revenue in 2025, equal to approximately USD 195.8 million, and is forecast to grow at a CAGR of about 6.7%. The region has extensive bronchiectasis expertise through specialist centers and collaborative registries, but device adoption remains uneven.

The EMBARC finding that 52.2% of patients received regular airway-clearance management while only 16.4% used a device reflects variation in clinical practice, physiotherapy capacity, reimbursement, and product access. The European authorization of brensocatib may increase specialist engagement and identify more patients with recurrent exacerbations, indirectly widening assessment for complementary airway-clearance therapy. 

Asia-Pacific accounted for an estimated 21.0% market share in 2025, representing approximately USD 152.3 million, and is expected to record the fastest regional CAGR of about 8.5% through 2032. The region contains a substantial but poorly quantified population with bronchiectasis, COPD, post-infectious lung damage, cystic fibrosis, and neuromuscular disease.

 

Market Outlook

The mucus clearance devices market is shifting from a cystic-fibrosis-centered category toward a broader chronic respiratory homecare market. Bronchiectasis diagnosis, COPD overlap, aging respiratory populations, neuromuscular care, and earlier hospital discharge are expanding the number of patients assessed for mechanical airway clearance.

Commercial success will depend on clinical evidence, reimbursement expertise, physician education, DME partnerships, patient onboarding, and ongoing service. Connected adherence tools and remote therapy reporting may become more valuable as payers examine whether high-value home equipment is being used and whether it reduces acute-care utilization.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 725.2 Million
Revenue Forecast in 2032	USD 1.16 Billion
Overall Growth Rate	CAGR of 6.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	High-Frequency Chest Wall Oscillation Systems, Positive Expiratory Pressure Devices, Oscillatory Positive Expiratory Pressure Devices, Mechanical Insufflation-Exsufflation Devices, Mechanical Percussion and Lung-Expansion Systems
By Application	Bronchiectasis, Cystic Fibrosis, Neuromuscular Disorders, Chronic Obstructive Pulmonary Disease, Primary Ciliary Dyskinesia, Acute and Postoperative Secretion Clearance
By End User	Homecare Settings, Hospitals, Outpatient Respiratory and Physiotherapy Centers, Long-Term Care and Post-Acute Facilities
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, and South Africa
Market Drivers	Rising prevalence of chronic respiratory and neuromuscular conditions, growing preference for home-based airway-clearance therapy, wider diagnosis and long-term management of bronchiectasis and cystic fibrosis, and increasing adoption of portable and patient-operated mucus clearance devices
Customization Option	Available upon request